195 related articles for article (PubMed ID: 36568640)
21. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer.
Bi Y; Li F; Ren J; Han X
Front Pharmacol; 2022; 13():1079707. PubMed ID: 36518678
[No Abstract] [Full Text] [Related]
22. Drug-eluting beads-transarterial chemoembolization plus microwave ablation is an effective and safe treatment strategy in treating hepatocellular carcinoma adjacent to gallbladder.
Cai L; Li H; Guo J; Zhao W; Li Y; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Li C
Am J Transl Res; 2021; 13(7):7677-7686. PubMed ID: 34377244
[TBL] [Abstract][Full Text] [Related]
23. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.
Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J
Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536
[TBL] [Abstract][Full Text] [Related]
24. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
Mukund A; Bhardwaj K; Choudhury A; Sarin SK
J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Ren K; Ren J; Ma J; Han X
Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
[No Abstract] [Full Text] [Related]
26. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm.
Cho SM; Chu HH; Kim JW; Kim JH; Gwon DI
Life (Basel); 2021 Apr; 11(4):. PubMed ID: 33919658
[TBL] [Abstract][Full Text] [Related]
27. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A randomized clinical trial.
Zhou TY; Tao GF; Zhou GH; Zhang YL; Zhu TY; Chen SQ; Wang HL; Wang BQ; Jing L; Chen F
Int J Surg; 2024 May; ():. PubMed ID: 38775550
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
[TBL] [Abstract][Full Text] [Related]
31. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.
Shi X; Wang Y; Ren J; Han X; Bi Y
BMC Cancer; 2023 Nov; 23(1):1144. PubMed ID: 38001447
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
[TBL] [Abstract][Full Text] [Related]
33. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y; Shi X; Ren J; Yi M; Han X
Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
[TBL] [Abstract][Full Text] [Related]
34. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
[TBL] [Abstract][Full Text] [Related]
36. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
37. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience.
Xiao YD; Ma C; Zhang ZS; Liu J
Cancer Manag Res; 2019; 11():1551-1557. PubMed ID: 30863165
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients.
Lee IJ; Lee JH; Lee YB; Kim YJ; Yoon JH; Yin YH; Lee M; Hur S; Kim HC; Jae HJ; Chung JW
Ther Adv Med Oncol; 2019; 11():1758835919866072. PubMed ID: 31447948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]